During the past decade, Cangzhou Central Hospital conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 2 clinical trials were completed, i.e. on average, 4.8% percent of trials that started reached the finish line to date. In the past 5 years, 29 clinical trials started and 2 clinical trials were completed. i.e. 6.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cangzhou Central Hospital" #1 sponsor was "Shanghai Henlius Biotech" with 4 trials, followed by "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Peking University First Hospital" with 2 trials sponsored and "Akeso" with 2 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cangzhou Central Hospital" #1 collaborator was "Cangzhou Central Hospital" with 3 trials as a collaborator, "The First Affiliated Hospital of Zhengzhou University" with 3 trials as a collaborator, "The Second Hospital of Hebei Medical University" with 3 trials as a collaborator, "Cangzhou People's Hospital" with 2 trials as a collaborator and "Peking University Shenzhen Hospital" with 2 trials as a collaborator. Other collaborators include 138 different institutions and companies that were collaborators in the rest 142 trials.

According to Clinical.Site data, the most researched conditions in "Cangzhou Central Hospital" are "Acute Ischemic Stroke" (3 trials), "Coronary Artery Disease" (3 trials), "Acute Coronary Syndrome" (2 trials), "Breast Cancer" (2 trials) and "Coronary Heart Disease" (2 trials). Many other conditions were trialed in "Cangzhou Central Hospital" in a lesser frequency.

Most popular intervention types in "Cangzhou Central Hospital" are "Drug" (30 trials), "Device" (5 trials), "Biological" (4 trials), "Other" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "HLX10" (2 trials), "Valsartan" (2 trials), "AK105 Injection" (1 trials) and "AK120" (1 trials). Other intervention names were less common.

The vast majority of trials in "Cangzhou Central Hospital" are 41 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Cangzhou Central Hospital". 4 are not yet recruiting, 14 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Cangzhou Central Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Cangzhou Central Hospital, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 9 trials that are defined as “Not Applicable".